NCT04134559View on ClinicalTrials.gov

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
Hepatocellular Carcinoma, ChildhoodFibrolamellar CarcinomaLiver CancerLiver Cancer, Pediatric
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.

Trial Locations (5)

45229

RECRUITING

Cincinnati Children's Medical Center, Cincinnati

77030

RECRUITING

Baylor College of Medicine, Houston

94143

RECRUITING

University of California San Francisco, San Francisco

02115

RECRUITING

Children's Hospital Boston, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Allison O'Neill, MD

OTHER